Advertisement

Advertisement
Immunotherapy
Multiple Myeloma

Highlighting Progress in Myeloma Treatment: POLLUX Trial Final Overall Survival Results With Daratumumab-Based Therapy

The updated results of the POLLUX trial, reported in the Journal of Clinical Oncology by Dimopoulos and colleagues and in this issue of The ASCO Post, showed...

Issues in Oncology

Making the Art of Oncology and Cancer Care Central to Her Presidential Term

Lynn M. Schuchter, MD, FASCO, has said that volunteering and working with ASCO over many years has been the highlight of her career. She served on...

Issues in Oncology

Partnering With Patients: The Cornerstone of Cancer Care and Research

The health and well-being of our clinicians, our communities, and our care systems need vigilance now more than ever to ensure we keep pace with the...


Advertisement
Hepatobiliary Cancer
Issues in Oncology
Pancreatic Cancer

KRYSTAL-1 Update: Adagrasib Yields Benefit in Variety of KRAS G12C–Mutated Tumors

In the phase I/II KRYSTAL-1 trial, the KRAS inhibitor adagrasib demonstrated clinical activity in previously treated patients with pancreatic ductal adenocarcinoma...

Hepatobiliary Cancer

Immunotherapy/Chemotherapy Combination Prolongs Survival in Advanced Biliary Tract Cancers

The addition of the checkpoint inhibitor pembrolizumab to chemotherapy with cisplatin/gemcitabine as first-line therapy improved overall survival...

Advertisement




Issues in Oncology

Joann G. Elmore, MD, MPH, on Cancer Diagnosis: When Pathologists Disagree, Artificial Intelligence May Help

Breast Cancer
Genomics/Genetics

OlympiA: Adjuvant Olaparib Extends Disease-Free Survival in BRCA-Mutated Early-Stage HER2-Negative Breast Cancer

One year of adjuvant therapy with the PARP inhibitor olaparib extended disease-free survival in patients with high-risk, early-stage, HER2-negative breast cancer with BRCA1/2 germline mutations, according to a prespecified interim analysis of the phase III OlympiA trial presented by Andrew Tutt, MB ...

Advertisement

Impact of Genes on Total Number and Type of Nevi

A study by Duffy et al in the Journal of Investigative Dermatology reported on specific gene variations affecting the number and types of moles on the body and their role in causing skin cancer.  “The goal was to investigate the genetic underpinnings of different mole classes, or...

Breast Cancer

Massimo Cristofanilli, MD, on Breast Cancer: Updated Analysis on Palbociclib Plus Fulvestrant

Prostate Cancer

Novel PSMA-Targeted Radiotherapy Improves Radiographic Progression-Free and Overall Survival in Metastatic Prostate Cancer

Lutetium-177–PSMA-617 (Lu-177–PSMA-617)—an investigational radioligand therapy—significantly improved radiographic progression-free survival and overall survival when added to standard of care compared with standard of care alone for men with metastatic castration-resistant prostate cancer whose...

FDA Approves New Pediatric Indication for Technetium Tc 99m Tilmanocept Injection

The Lymphoseek (technetium Tc 99m tilmanocept) injection—a radiopharmaceutical agent specifically designed for targeted lymphatic mapping and guiding sentinel lymph node biopsies—has been approved for pediatric use by the U.S. Food and Drug Administration (FDA). "This new indication opens the door ...

Gemcitabine/Eribulin in Cisplatin-Ineligible Metastatic Urothelial Carcinoma

In the final analysis from a phase II California Cancer Consortium trial (NCI-9653) reported in the Journal of Clinical Oncology, Sadeghi et al found the combination of gemcitabine and eribulin showed activity in cisplatin-ineligible patients with metastatic urothelial carcinoma. Study Details...

Prostate Cancer

Michael J. Morris, MD, on Prostate Cancer: LuPSMA in the Metastatic Setting

Survivorship

Study Examines Barriers to Survivorship Care

Even among a large group of cancer survivors who were mostly insured, college-educated, and had annual incomes above the national average, up to 10% delayed care in the previous 12 months because they simply could not afford out-of-pocket expenses like copays and deductibles. These findings were...

Advertisement

Deintensified Chemoradiotherapy for HPV-Associated Oropharyngeal Squamous Cell Carcinoma

In a phase II trial reported in the Journal of Clinical Oncology, Chera et al found that deintensified chemoradiotherapy produced favorable outcomes in human papillomavirus (HPV)-associated oropharyngeal squamous cell carcinoma. Study Details In the multicenter trial, 114 patients were recruited...